ArticleAnnals of hematology2025

An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.

Danilo De Novellis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.